Michael Belliveau has been at Clark+Elbing, a Boston patent prosecution firm, since 1998 and a partner since 2006. His work includes the preparation of patentability, non-infringement, and freedom-to-operate opinions.
Michael works with clients to protect innovations related to small molecule therapeutics for the treatment of bacterial and fungal infections, cancer, neurological disorders, and inflammation. His other areas of focus include drug discovery, molecular diagnostics, DNA and protein chip-based technologies, stem cells, and human gene therapy. He also performs patent due diligence analyses for venture capital investors.
Michael's doctoral research at Harvard University employed cellular and molecular techniques, confocal microscopy, and fluorescence-activated cell sorting to study neural progenitor cell specification and differentiation.